Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Core Insights - Boundless Bio is advancing its pipeline focused on extrachromosomal DNA (ecDNA) to develop innovative therapies for oncogene-amplified cancers, with ongoing enrollment in the BBI-355/BBI-825 combination arm of the POTENTIATE trial and plans to initiate a first-in-human clinical trial for BBI-940 in the first half of 2026 [2][3][5] Financial Highlights - As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments totaling $117.6 million, which is expected to support operations into the first half of 2028 [7][10] - Research and Development (R&D) expenses for Q3 2025 were $10.7 million, a decrease from $14.1 million in Q3 2024, while General and Administrative (G&A) expenses were $4.5 million, slightly down from $4.6 million in the same period [7][10] - The net loss for Q3 2025 was $13.9 million, compared to a net loss of $16.5 million for Q3 2024, indicating an improvement in financial performance [7][10] Research and Development Updates - The POTENTIATE clinical trial is actively enrolling patients for the combination of BBI-355 and BBI-825, with initial proof-of-concept clinical data expected within the existing cash runway timeline [3][4] - BBI-940, a novel Kinesin degrader targeting ecDNA segregation, is on track for investigational new drug submission, with a first-in-human clinical trial anticipated to start in the first half of 2026 [1][5]